Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study.

albumin-bound paclitaxel - Generic mfg.

cisplatin - Generic mfg.

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

Gilotrif (afatinib) - Boehringer Ingelheim

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. (PubMed, J Immunother Cancer) - Sep 13, 2026 - P2 | "We report, for the first time, the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with afatinib in patients with LA-HNSCC. Neoadjuvant treatment potentially induced an immune-enhanced tumor microenvironment. Further evaluation in large-scale clinical trials with longer follow-up periods is needed."
IO biomarker • Journal • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8

http://www.ncbi.nlm.nih.gov/pubmed/42731876

Dejuan Wang; Fei Chen; Feng Wang; Huaju Yang; Huijiao Chen; Jing Jin; Jun Liu; Leyu Li; Xingchen Peng; Yiqiao Luo; Yiyan Pei; Zhigong Wei

Sep 13, 2026